NEW YORK (AP) -- Two analysts starting covering biotech drugmaker Chimerix Inc. with top ratings on Monday, pointing to the company's experimental drug CMX001. THE OPINION: Cowen & Co. analyst Phil ...

There’s another round of bad news to report for Chimerix. After seeing its stock price crushed at the end of last year on the failure of its first Phase III study for the once-promising antiviral ...

We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where Chimerix Inc. (NASDAQ:CMRX) stands against other healthcare ...

Chimerix cell biologist Phiroze Sethna draws samples to help him begin to grow and study new cells in his anti-viral research in 2011. Chimerix’s value has plummeted from $2.5 billion last summer to ...

(Reuters) - Chimerix Inc said on Friday it had been awarded a contract worth up to $25.3 million by Canada for its smallpox drug, likely to used to treat monkeypox as the viral infection spreads ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Chimerix ( (CMRX)) has shared an ...

DURHAM, NC, February 14, 2011 – Chimerix, Inc., a pharmaceutical company developing orally-available broad spectrum antiviral therapeutics, today announced the completion of a $45 million Series F ...

-Transaction represents total cash consideration of approximately $935 million, or $8.55 per share- DUBLIN and DURHAM, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ...

- Small Business Administration Rules that SIGA Technologies is Not a Small Business, Rendering It Ineligible for BARDA Contract RESEARCH TRIANGLE PARK, NC, November 7, 2010 - Chimerix, Inc., a ...

We recently compiled a list of the Why These 24 Stocks Are Skyrocketing. In this article, we are going to take a look at where Chimerix, Inc. (NASDAQ:CMRX) stands against the other stocks. One of the ...

Shares of Chimerix Inc. shot up 14.4% in premarket trading Monday, after the biopharmaceutical company said it will sell exclusive rights to its smallpox treatment, including Tembexa, to Emergent ...